Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
Management will also participate in four upcoming investor healthcare conferences
SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the same day after the market closes.
During the call, Myriad management will provide a financial overview and business update of the company’s performance for the first quarter 2024.
A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at . To participate in the live conference call via telephone, please . Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at following the call.
Q2 Investor Conferences
Management will also be participating in the following investor conferences:
- The Bank of America Securities Health Care Conference with a presentation from Sam Raha, chief operating officer, and Scott Leffler, chief financial officer, on Tuesday, May 14, 2024 at 8:15pm ET.
- The Piper Sandler Virtual Cancer Testing Day with a presentation from Dale Muzzey, chief scientific officer, on May 21, 2024 at 11am ET.
- The Leerlink Partners Healthcare Crossroads Conference with a presentation from Paul J. Diaz, president and CEO, and Scott Leffler, chief financial officer, on May 30, 2024 at 11am ET.
- The 45th Annual Global Goldman Sachs Global Healthcare Conference with a presentation from Paul J. Diaz, president and CEO, and Scott Leffler, chief financial officer, on June 12, 2024 at 3:20pm ET.
Live and archived webcasts of all presentations can be viewed at .
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .
Investor Contact
Matt Scalo
(801) 584-3532
Media Contact
Glenn Farrell
(385) 318-3718
